XETRA

EQS-News:  Newron appoints Margarita Chavez as board advisor

Retrieved on: 
Monday, October 2, 2023

Margarita Chavez, former Managing Director at AbbVie Ventures, to be nominated for election to the Board of Directors at the Ordinary AGM 2024

Key Points: 
  • Margarita Chavez, former Managing Director at AbbVie Ventures, to be nominated for election to the Board of Directors at the Ordinary AGM 2024
    Milan, Italy, October 2, 2023 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous (CNS) system, today announced that Margarita Chavez has been appointed as an advisor to the Board of Directors of Newron, bringing significant pharmaceutical business development (BD) and dealmaking expertise.
  • It is intended that Margarita Chavez will be nominated for election to the Board of Directors at Newron’s next Ordinary Annual General Meeting (AGM) of Shareholders in spring 2024.
  • Margarita Chavez brings to Newron over 20 years of dealmaking expertise and leadership in the pharmaceutical industry.
  • Ulrich Köstlin, Chairman of the Board of Directors of Newron, commented: “We are delighted that Margarita will be supporting us with her vast international dealmaking expertise as a Board advisor and we are convinced that she will as of the AGM 2024 significantly strengthen our Board of Directors as new member.

Cosmo and Hikma Sign License Agreement for Winlevi® in 17 Middle Eastern and North African Countries

Retrieved on: 
Monday, October 2, 2023

Under the terms of the agreement, Hikma will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to register and commercialize Winlevi® in 17 Middle Eastern and North African countries.

Key Points: 
  • Under the terms of the agreement, Hikma will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to register and commercialize Winlevi® in 17 Middle Eastern and North African countries.
  • Cassiopea will receive an upfront payment of USD 750,000 in addition to potential regulatory and sales milestones.
  • Cassiopea will be the exclusive supplier of the product at a price calculated on the net sales.
  • Over 15,000 US health care providers have prescribed Winlevi® to date which represents 88% of total health care providers in dermatology.

EQS-News: Advanced Blockchain significantly improves earnings in the first half of 2023

Retrieved on: 
Friday, September 29, 2023

29 September 2023 – Advanced Blockchain AG ("AB," Scale Frankfurt, Primary Market Düsseldorf, XETRA: ISIN DE000A0M93V6), a leading incubator, architect, and investor in the blockchain industry, developed according to plan in the first half of the year.

Key Points: 
  • 29 September 2023 – Advanced Blockchain AG ("AB," Scale Frankfurt, Primary Market Düsseldorf, XETRA: ISIN DE000A0M93V6), a leading incubator, architect, and investor in the blockchain industry, developed according to plan in the first half of the year.
  • In H1 2023, Advanced Blockchain invested around €3 million in promising projects and disruptive technologies.
  • Simon Telian, CEO of Advanced Blockchain commented, "With the crypto market continuing to be highly volatile, we were able to significantly improve earnings as planned.
  • In fiscal year 2023, Advanced Blockchain remains focused on sustainable growth, with a simultaneous focus on cost structures.

EQS-News: Cinven to launch public acquisition offer for SYNLAB AG

Retrieved on: 
Friday, September 29, 2023

(“Ephios”), an entity controlled by funds managed and/or advised by Cinven, today announced its decision to launch a public acquisition offer (the “Offer”) for all outstanding shares of SYNLAB AG (“SYNLAB” or the “Company”) not directly held by it.

Key Points: 
  • (“Ephios”), an entity controlled by funds managed and/or advised by Cinven, today announced its decision to launch a public acquisition offer (the “Offer”) for all outstanding shares of SYNLAB AG (“SYNLAB” or the “Company”) not directly held by it.
  • Cinven has not acquired any SYNLAB share from any shareholder above the offer price and does not intend to do so.
  • Cinven has secured financing commitments for the acquisition of all outstanding shares in SYNLAB AG not directly held by Ephios.
  • The offer document (once available) and other information relating to the Offer will be published on the following website: https://www.ephios-offer.com/

EQS-News: SYNLAB AG: SYNLAB enters into investment agreement relating to a public acquisition offer by Cinven

Retrieved on: 
Friday, September 29, 2023

The SYNLAB Management Board and Supervisory Board know Cinven well as a trusted and supportive long-standing shareholder and anticipate a good further cooperation.

Key Points: 
  • The SYNLAB Management Board and Supervisory Board know Cinven well as a trusted and supportive long-standing shareholder and anticipate a good further cooperation.
  • Both will carefully review the offer document following its publication and will then issue their reasoned statement on the adequacy of the Offer.
  • In the investment agreement, Cinven commits to support the strategic ambitions of SYNLAB to strengthen its position as an international leader in medical diagnostic services and specialty testing.
  • Cinven does not intend to seek or enter into a domination and profit and loss transfer agreement (DPLTA) with SYNLAB.

EQS-News: Bank of America Securities Europe SA: Pre-stabilisation Period Announcement

Retrieved on: 
Wednesday, September 27, 2023

However, stabilisation may not necessarily occur and any stabilisation action, if begun, may cease at any time.

Key Points: 
  • However, stabilisation may not necessarily occur and any stabilisation action, if begun, may cease at any time.
  • Any stabilisation action or over‑allotment shall be conducted in accordance with all applicable laws and rules.
  • This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.
  • This announcement is not an offer of securities for sale into the United States.

EQS-News: Kontron AG resolves on a new share buyback program of up to EUR 70 million

Retrieved on: 
Wednesday, September 27, 2023

On 3 February 2023, the Executive Board of Kontron AG ( www.kontron.com , ISIN AT0000A0E9W5, WKN A0X9EJ, KTN) resolved on the implementation of a new buyback program for own shares ("Buyback Program I 2023") in accordance with § 65 para.

Key Points: 
  • On 3 February 2023, the Executive Board of Kontron AG ( www.kontron.com , ISIN AT0000A0E9W5, WKN A0X9EJ, KTN) resolved on the implementation of a new buyback program for own shares ("Buyback Program I 2023") in accordance with § 65 para.
  • On 27.09.2023, the Executive Board of Kontron AG resolved on the implementation of a new buyback program for own shares ("Buyback Program II 2023") in accordance with § 65 para.
  • The share buyback under the Buyback Program II 2023 will be made for the account of Kontron AG and managed by a credit institution.
  • The volume under the Buyback Program II amounts to up to 4 million of shares and the Buyback Program II 2023 is planned to commence on Monday, 02.10.2023 (terms of the Buyback Program II are outlined below).

Cosmo and Glenmark announce the signing of Distribution and License Agreements for Winlevi® in Europe and South Africa

Retrieved on: 
Wednesday, September 27, 2023

MUMBAI, India and DUBLIN, Sept. 27, 2023 /PRNewswire/ --  Cosmo Pharmaceuticals N.V. (SIX: COPN), (XETRA: C43) ("Cosmo") and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. ("Glenmark"), today announced the signing of distribution and license agreements for Winlevi® (clascoterone cream 1%) in Europe and South Africa.

Key Points: 
  • MUMBAI, India and DUBLIN, Sept. 27, 2023 /PRNewswire/ --  Cosmo Pharmaceuticals N.V. (SIX: COPN), (XETRA: C43) ("Cosmo") and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. ("Glenmark"), today announced the signing of distribution and license agreements for Winlevi® (clascoterone cream 1%) in Europe and South Africa.
  • Alessandro Della Chà, CEO of Cosmo, said, "We are very pleased to partner with Glenmark.
  • Their strong expertise in the commercialization of pharmaceutical compounds gives us great confidence in their ability to successfully market Winlevi®.
  • Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements.

Cosmo and Glenmark announce the signing of Distribution and License Agreements for Winlevi® in Europe and South Africa

Retrieved on: 
Wednesday, September 27, 2023

MUMBAI, India and DUBLIN, Sept. 27, 2023 /PRNewswire/ --  Cosmo Pharmaceuticals N.V. (SIX: COPN), (XETRA: C43) ("Cosmo") and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. ("Glenmark"), today announced the signing of distribution and license agreements for Winlevi® (clascoterone cream 1%) in Europe and South Africa.

Key Points: 
  • MUMBAI, India and DUBLIN, Sept. 27, 2023 /PRNewswire/ --  Cosmo Pharmaceuticals N.V. (SIX: COPN), (XETRA: C43) ("Cosmo") and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. ("Glenmark"), today announced the signing of distribution and license agreements for Winlevi® (clascoterone cream 1%) in Europe and South Africa.
  • Alessandro Della Chà, CEO of Cosmo, said, "We are very pleased to partner with Glenmark.
  • Their strong expertise in the commercialization of pharmaceutical compounds gives us great confidence in their ability to successfully market Winlevi®.
  • Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements.

EQS-News: OHB SE: Management Board and Supervisory Board of OHB SE recommend accepting the voluntary public takeover offer by KKR

Retrieved on: 
Monday, September 25, 2023

Management Board and Supervisory Board of OHB SE welcome strategic partnership with KKR and recommend shareholders to accept the takeover offer.

Key Points: 
  • Management Board and Supervisory Board of OHB SE welcome strategic partnership with KKR and recommend shareholders to accept the takeover offer.
  • The Management Board and the Supervisory Board of the German space and technology company OHB SE (“OHB”) today published a joint reasoned statement pursuant to Section 27 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz, “WpÜG”) on the voluntary public takeover offer by Orchid Lux HoldCo S.à r.l.
  • In it, they conclude that the Bidder's takeover offer is in the best interest of OHB, its shareholders, employees and other stakeholders.
  • At the same time, my family retains permanent control as majority shareholder.”
    Robert Wethmar, chairman of the Supervisory Board of OHB, added: “After careful and thorough review, the Management Board and the Supervisory Board recommend accepting the offer.